Fig. 6: NK cells suppress gastric cancer metastasis.
From: Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease
a, Kaplan–Meier survival curves of immunocompetent C57BL/6 mice (BL/6, green; same cohort as shown in Fig. 2c) and immunodeficient R2G2 mice (purple, n = 8 mice) with electroporation-induced MYC-Apc−/− gastric cancer. b, H&E staining of liver metastases from mice in a. Representative of n = 5 mice (BL/6) or n = 8 mice (R2G2) per group. c, Quantification of the number of liver metastases (left) and the percentage area of total liver occupied by metastases (right) from a subset of mice in a (BL/6 n = 5 mice; R2G2 n = 8 mice). d, Kaplan–Meier survival curves of BL/6 MYC-Apc−/− gastric cancer EPO-GEMMs treated with an NK1.1-targeting antibody (purple, n = 22 mice) or IgG control (green, n = 21 mice). e, Quantification of the number of liver metastases (left) and the percentage area of total liver occupied by the metastases (right) in a randomly chosen subset of mice from d (IgG n = 7 mice; NK1.1 n = 7 mice). Statistical analyses were one-sided log-rank test (a,d) and two-tailed Mann–Whitney U-test (c,e).
